Ibuprofen Is Cleared by an Enzyme That Roughly a Third of People Carry a Slower Version Of
CYP2C9 metabolises most NSAIDs, and reduced-function variants are common. International prescribing guidelines already tell clinicians what to do about it — which makes this one of the few genetic results with a concrete, actionable meaning.
You take two ibuprofen for a bad back. So does the person next to you. Twelve hours later one of you still has a meaningful amount of the drug in circulation.
Most genetic findings are statistical whispers. Pharmacogenomics is the corner of the field where the signal is loud enough that prescribing guidelines exist.
NSAIDs — ibuprofen, naproxen, celecoxib, meloxicam, piroxicam — are among the most widely taken drugs in the world. Many are cleared primarily by a single enzyme, CYP2C9. And the gene encoding it is meaningfully variable.
The guideline
The Clinical Pharmacogenetics Implementation Consortium publishes peer-reviewed, regularly updated guidance translating genotype into prescribing action. Their NSAID guideline covers exactly this (Theken et al., Clinical Pharmacology & Therapeutics, 2020, PMID: 32189324).
The logic is straightforward. Reduced-function CYP2C9 alleles — most commonly *2 (rs1799853) and *3 (rs1057910) — slow clearance. Slower clearance means higher drug exposure for the same dose, and NSAID side effects, particularly gastrointestinal bleeding, are exposure-dependent.
For poor metabolisers, CPIC recommends starting at a reduced dose of the affected NSAIDs, or choosing one not primarily cleared by CYP2C9, with careful monitoring. The effect is most pronounced for drugs with long half-lives, such as piroxicam and meloxicam.
Why this one is different
Compare it with almost everything else in consumer genetics.
| Typical GWAS trait | CYP2C9 and NSAIDs | |
|---|---|---|
| Effect size | Tiny, spread over hundreds of variants | Large, driven by a few alleles |
| Mechanism | Often unknown | Known enzyme, known substrate |
| Actionable | Rarely | Yes — published dosing guidance |
This is the difference between a variant that shifts a population average and a variant that changes what a clinician should do on a Tuesday afternoon.
The limits, which are real
Allele frequencies vary substantially between populations, and consumer arrays do not capture every reduced-function allele. A result showing normal metabolism does not guarantee a normal-function genotype — it means no tested variant was found.
Genotype is one input. Age, kidney function, existing gastrointestinal risk, alcohol use and co-prescribed drugs all affect NSAID safety, often more than CYP2C9 status does.
Nothing here is a reason to change a prescription on your own. If your genotype suggests reduced metabolism, that is a conversation to have with a doctor or pharmacist — who may well already have access to this guideline. Do not stop, start or re-dose a medication based on an app.
What the app reports
Drug Metabolism NSAIDs reads your CYP2C9 genotype and translates it into the metaboliser categories used in the pharmacogenomics literature - it reports where you would have been grouped in that research, not a personal prediction about how a drug will affect you.
Per the developer's disclaimer, it "is not a diagnosis, a prediction, or a predisposition score" but "an implementation of the findings in referenced papers for research purposes only."
What makes it worth reading anyway is that, unusually, there is a published clinical guideline sitting behind the result — and a specific, sensible thing to ask your doctor about if it flags something.